
|Poll|March 7, 2011
Pruritic Discoloration Following ABVD Therapy
Author(s)Ted Rosen, MD
Advertisement
A 26-year-old man was diagnosed with the nodular sclerosing subtype of Hodgkin lymophoma, stage II-A. He was started on cyclic combination chemotherapy consisting of adriamycin, bleomycin, vinblastine, and dacarbazine ("ABVD" therapy). Although generally tolerating the treatment well, about 2 weeks after the second cycle of treatment, he noted and complained about slightly pruritic discoloration of his trunk. His left chest is depicted in the figure.
Which statement is true regarding this phenomenon?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
2
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
3
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
4
What is the Future of TIL Therapy in Metastatic Melanoma?
5



















































